A 58-year-old man known to have morbid obesity, dyslipidemia, hypothyroidism, and a remote history of pleural Tuberculosis (TB) was diagnosed with IgG kappa multiple myeloma in July 2015. He received induction with bortezomib, lenalidomide, and dexamethasone followed by auto-HCT with melphalan MAC conditioning after achieving a very good partial response (VGPR). He was maintained on lenalidomide with dexamethasone, but he relapsed in December 2017 and was treated with carfilzomib, lenalidomide, and dexamethasone. In late May 2020, while on therapy, he developed a sore throat, fever, and runny nose. He tested positive by PCR for SARS-Cov2 infection. He recovered well after seven days of initial symptoms. Repeat nasal SARS-Cov2 PCR on August 20, 2020, was negative, and his SARS-Cov2 total antibody test was reactive.